These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 34814865)

  • 41. Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials.
    Neighbors M; Cabanski CR; Ramalingam TR; Sheng XR; Tew GW; Gu C; Jia G; Peng K; Ray JM; Ley B; Wolters PJ; Collard HR; Arron JR
    Lancet Respir Med; 2018 Aug; 6(8):615-626. PubMed ID: 30072107
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fibroblast activation protein and disease severity, progression, and survival in idiopathic pulmonary fibrosis.
    Prior TS; Hoyer N; Davidsen JR; Shaker SB; Hundahl MP; Lomholt S; Deleuran BW; Bendstrup E; Kragstrup TW
    Scand J Immunol; 2024 Sep; 100(3):e13392. PubMed ID: 38849304
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
    Corral M; DeYoung K; Kong AM
    BMC Pulm Med; 2020 Jul; 20(1):188. PubMed ID: 32652979
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diagnostic and treatment standards in idiopathic pulmonary fibrosis in the era of antifibrotic drugs in Poland: A real-world practice survey.
    Majewski S; Lewandowska K; Martusewicz-Boros MM; Piotrowski WJ
    Adv Respir Med; 2019; 87(6):221-230. PubMed ID: 31970724
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.
    Raghu G; Brown KK; Collard HR; Cottin V; Gibson KF; Kaner RJ; Lederer DJ; Martinez FJ; Noble PW; Song JW; Wells AU; Whelan TP; Wuyts W; Moreau E; Patterson SD; Smith V; Bayly S; Chien JW; Gong Q; Zhang JJ; O'Riordan TG
    Lancet Respir Med; 2017 Jan; 5(1):22-32. PubMed ID: 27939076
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Endotrophin and C6Ma3, serological biomarkers of type VI collagen remodelling, reflect endoscopic and clinical disease activity in IBD.
    Lindholm M; Godskesen LE; Manon-Jensen T; Kjeldsen J; Krag A; Karsdal MA; Mortensen JH
    Sci Rep; 2021 Jul; 11(1):14713. PubMed ID: 34282237
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
    Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
    PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cathepsin-S degraded decorin are elevated in fibrotic lung disorders - development and biological validation of a new serum biomarker.
    Kehlet SN; Bager CL; Willumsen N; Dasgupta B; Brodmerkel C; Curran M; Brix S; Leeming DJ; Karsdal MA
    BMC Pulm Med; 2017 Aug; 17(1):110. PubMed ID: 28793886
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cutaneous T-cell-attracting chemokine as a novel biomarker for predicting prognosis of idiopathic pulmonary fibrosis: a prospective observational study.
    Niwamoto T; Handa T; Murase Y; Nakatsuka Y; Tanizawa K; Taguchi Y; Tomioka H; Tomii K; Kita H; Uyama M; Tsuchiya M; Emura M; Kawamura T; Arai N; Arita M; Uno K; Yoshizawa A; Uozumi R; Yamaguchi I; Matsuda F; Chin K; Hirai T
    Respir Res; 2021 Jun; 22(1):181. PubMed ID: 34158044
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.
    Aono Y; Nakamura Y; Kono M; Nakamura H; Yokomura K; Imokawa S; Toyoshima M; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T
    Ther Adv Respir Dis; 2020; 14():1753466620953783. PubMed ID: 32928050
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Potential role of SIRT-1 and SIRT-3 as biomarkers for the diagnosis and prognosis of idiopathic pulmonary fibrosis.
    Perrotta F; D'Agnano V; Mariniello DF; Castaldo G; Vitale M; Cazzola M; Bianco A; Scialò F
    Respir Res; 2024 Apr; 25(1):189. PubMed ID: 38678247
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis.
    Sugino K; Ono H; Watanabe N; Ando M; Tsuboi E; Homma S; Kishi K
    BMC Pulm Med; 2021 Jul; 21(1):218. PubMed ID: 34246227
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Associations of Serological Biomarkers of sICAM-1, IL-1
    Li X; Zhou Y; Zou R; Chen H; Liu X; Qiu X; Xiao Y; Cai H; Dai J
    Mediators Inflamm; 2020; 2020():4534272. PubMed ID: 32694925
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antithrombin III as predictive indicator of survival in idiopathic pulmonary fibrosis (IPF) patients treated with nintedanib: a preliminary study.
    Bergantini L; d'Alessandro M; Cameli P; Carleo A; Landi C; Vietri L; Lanzarone N; Pieroni M; Sestini P; Bargagli E
    Intern Med J; 2021 May; 51(5):705-711. PubMed ID: 32040256
    [TBL] [Abstract][Full Text] [Related]  

  • 55. C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis.
    Vuga LJ; Tedrow JR; Pandit KV; Tan J; Kass DJ; Xue J; Chandra D; Leader JK; Gibson KF; Kaminski N; Sciurba FC; Duncan SR
    Am J Respir Crit Care Med; 2014 Apr; 189(8):966-74. PubMed ID: 24628285
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical significance of serum S100 calcium-binding protein A4 in idiopathic pulmonary fibrosis.
    Akiyama N; Hozumi H; Isayama T; Okada J; Sugiura K; Yasui H; Suzuki Y; Kono M; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Nakamura Y; Suda T
    Respirology; 2020 Jul; 25(7):743-749. PubMed ID: 31597225
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The serum KL-6 levels in untreated idiopathic pulmonary fibrosis can naturally decline in association with disease progression.
    Ishii H; Kushima H; Kinoshita Y; Fujita M; Watanabe K
    Clin Respir J; 2018 Sep; 12(9):2411-2418. PubMed ID: 30015394
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biomarkers of collagen turnover are related to annual change in FEV
    Leeming DJ; Byrjalsen I; Sand JMB; Bihlet AR; Lange P; ; Thal-Singer R; Miller BE; Karsdal MA; Vestbo J
    BMC Pulm Med; 2017 Dec; 17(1):164. PubMed ID: 29202744
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience.
    Rivera-Ortega P; Hayton C; Blaikley J; Leonard C; Chaudhuri N
    Ther Adv Respir Dis; 2018; 12():1753466618800618. PubMed ID: 30249169
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum high-mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis.
    Yamaguchi K; Iwamoto H; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Ohshimo S; Fujitaka K; Hamada H; Hattori N
    Respirology; 2020 Mar; 25(3):275-280. PubMed ID: 31270920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.